Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Company Information
About this company
Key people
David Weinstein
Chief Executive Officer, Director
Nathen Fuentes
Chief Financial Officer
Douglas W. Calder
Independent Director
Mark Anthony Collins
Independent Director
James A. Mcnulty
Independent Director
Click to see more
Key facts
- Shares in issue23.43m
- EPICLNAI
- ISINUS29350E2037
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$16.05m
- Employees29
- ExchangeNASDAQ
- Index
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.